article thumbnail

Telemedicine and the Prescribing of Controlled Substances After the End of The Covid-19 Pandemic Emergency: DEA Announces Two Significant Proposed Rules: Read the Summary Below, But Learn All the Details and More at HPM’s Webinar on March 23, 2023 (Details Forthcoming….)

The FDA Law Blog

Comment topics suggested by DEA include the following: Whether the rule should limit the issuance of prescriptions for controlled medications to FDA-approved indications contained in the labeling for those medications. Helpful practitioner prescribing guidance is set forth in a simplified document here. Stay tuned.

article thumbnail

FDA’s New Draft Guidance on 510(k) Implant Devices: What You Need to Know

The FDA Law Blog

By Philip Won & Véronique Li, Senior Medical Device Regulation Expert — As we recently blogged , FDA released three draft guidance documents to help enhance the predictability, consistency, and transparency of the 510(k) program. One of these documents focuses on “ Evidentiary Expectations for 510(k) Implant Devices.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

New IFPMA and EFPIA guidance on use of social media by the pharmaceutical industry

pharmaphorum

WebinarsWebinars, whether live streamed or on-demand, can be used for communication with HCPs, HCOs, and POs. A company is responsible for the content of webinars and should take reasonable steps to ensure the audience is targeted and well defined.

article thumbnail

Ensuring Medication Safety Through Automation Designed to Support ISMP Best Practices

Omnicell

Omnicell continues to collaborate with ISMP to improve pharmacy-nursing efficiency, reduce medication errors during dispensing, and support accurate medication tracking and documentation of inventory and deter drug diversion. Watch this webinar to learn more about how automated dispensing systems support ISMP guidelines for medication safety.

article thumbnail

Pharma 4.0™ Is Gaining Momentum and Driving Innovation

ISPE

In the years leading up to 2022, numerous publications were issued; networking events, webinars, and conferences were held; and regulatory panel discussions with regulators performed. Is the vendors’ documentation complete in order to assess GxP risks and GxP compliance? and management communication strategy.